On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab), an immunotherapy developed by Merck Sharp Dohme. This approval specifically pertains to an efficacy-related application, indicating an expansion of the drug's approved therapeutic uses based on new data.
Background
Pembrolizumab, marketed as Keytruda, is a well-established programmed death receptor-1 (PD-1) blocking antibody. As an immunotherapy, it works by enhancing the body's immune response to fight cancer cells. Prior to this supplemental approval, Keytruda had already received several FDA approvals for various cancer indications, establishing its role as a significant treatment option across multiple tumor types. Supplemental applications for efficacy typically involve new clinical data demonstrating the drug's effectiveness in an additional patient population, for a new indication, or in a different treatment setting, thereby broadening its clinical utility.
What this means
The FDA's supplemental approval for Keytruda (pembrolizumab) based on efficacy data signifies that the drug has demonstrated a clinically meaningful benefit in a new context. While the specific details of the expanded indication or patient population are not provided in the summary of the approval, such efficacy-based supplemental approvals are crucial for expanding treatment options for patients. For clinicians, this means that Keytruda becomes an approved treatment for an additional condition or patient group, offering more therapeutic choices. Researchers will note this as a successful advancement in the development of PD-1 inhibitors, reinforcing the broad applicability of this class of drugs in oncology. Patient advocates can highlight this as a positive development, potentially increasing access to an effective treatment for a wider range of cancer patients.
Source
The information regarding this supplemental FDA approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125514 S-24, an efficacy-related supplemental application for Keytruda (pembrolizumab), was granted on September 22, 2017, and is publicly available on accessdata.fda.gov.